Earnings History Data for Bellicum Pharmaceuticals, Inc. (BLCM) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.
See the full list of available companies here.

Bellicum Pharmaceuticals, Inc.

Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company's lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas.
Release Date Time Est. Time Symbol Name Market Cap (M) Rep. EPS Est. EPS Last years EPS SeekingAlpha Headline Price Change Ext. Hours Price Ext. Hours Change 52 Week Range Volume Avg. Volume Ext. Hours Volume Top Mover
30-03-2021 AH 4:05 PM ET
(Mar 30)		 BLCM Bellicum Pharmaceuticals, Inc. 24.16 -3.05 0.00 -2.94 Bellicum Pharmaceuticals EPS beats by $2.04
[3/30/2021 4:14 PM]		 3.75 0.37 
(10.95%)		 3.64 0.26 
(7.69%)		 2.62 - 9.56 625,392 250,000 3,255
06-08-2020 AH 4:05 PM ET
(Aug 6)		 BLCM Bellicum Pharmaceuticals, Inc. 36.01 -2.47 0.00 -5.80 Bellicum Pharmaceuticals EPS misses by $5.68
[8/6/2020 4:10 PM]		 7.57 0.08 
(1.06%)		 7.55 0.06 
(0.80%)		 3.32 - 27.90 29,695 27,167 142